Clinical syndrome

: Pulmonary arterial hypertension is a progressive disorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, resulting in increased pulmonary vascular resistance and pulmonary pressures. This leads to reduced cardiac output, right heart failure, and ultimately death. In this review, we attempt to answer some important questions commonly asked by patients diagnosed with pulmonary arterial hypertension pertaining to the disease, and aim to provide an explanation in terms of classification, diagnosis, pathophysiology, genetic causes, demographics, and prognostic factors. Furthermore, important molecular pathways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial and smooth muscle proliferation. ( Circ Res . 2014;115:115-130.) The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling Ventricular

[1]  Heritable pulmonary arterial hypertension , 2020, Definitions.

[2]  M. Gassmann,et al.  AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. , 2014, European heart journal.

[3]  G. Gildengorin,et al.  A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes , 2013, Haematologica.

[4]  M. Gladwin,et al.  Antioxidant therapy for the treatment of pulmonary hypertension. , 2013, Antioxidants & redox signaling.

[5]  J. Marks,et al.  Superoxide generated at mitochondrial complex III triggers acute responses to hypoxia in the pulmonary circulation. , 2013, American journal of respiratory and critical care medicine.

[6]  P. Steendijk,et al.  Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. , 2012, American journal of respiratory and critical care medicine.

[7]  R. Dweik,et al.  Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[8]  M. Eghbali,et al.  Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. , 2012, American journal of respiratory and critical care medicine.

[9]  L. Rubin The 6-minute walk test in pulmonary arterial hypertension: how far is enough? , 2012, American journal of respiratory and critical care medicine.

[10]  M. Puhan,et al.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[11]  D. Tsikas Letter by Tsikas regarding article, "dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase". , 2012, Circulation.

[12]  Man Tsuey Tse Trial watch: Phase III success for first-in-class pulmonary hypertension drug , 2012, Nature reviews. Drug discovery.

[13]  P. Gargiulo,et al.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.

[14]  B. Kang,et al.  The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. , 2012, American journal of respiratory cell and molecular biology.

[15]  R. Frantz,et al.  Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  H. Palevsky,et al.  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[17]  M. Gladwin,et al.  Reactive oxygen and nitrogen species in pulmonary hypertension. , 2012, Free radical biology & medicine.

[18]  A. Torbicki,et al.  Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.

[19]  R. Benza,et al.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.

[20]  L. Lopes,et al.  Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. , 2011, Free radical biology & medicine.

[21]  C. Tysk,et al.  Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[22]  Lan Zhao,et al.  Safety of sapropterin dihydrochloride (6r–bh4) in patients with pulmonary hypertension , 2011, Experimental lung research.

[23]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[24]  S. Suissa,et al.  Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. , 2010, Circulation.

[25]  Gene Kim,et al.  Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target , 2010, Circulation.

[26]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[27]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[28]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[29]  M. Gladwin,et al.  Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase–Dependent Nitric Oxide Generation , 2010, Circulation.

[30]  Sanjiv J. Shah,et al.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[31]  P. Hassoun,et al.  Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. , 2009, Circulation.

[32]  A. Malik,et al.  Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.

[33]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[34]  J. Stasch,et al.  Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension , 2009, ChemMedChem.

[35]  F. Parl,et al.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females , 2009, European Respiratory Journal.

[36]  Michael P. Murphy,et al.  How mitochondria produce reactive oxygen species , 2008, The Biochemical journal.

[37]  N. Rudarakanchana,et al.  Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. , 2008, Human molecular genetics.

[38]  J. Cogan,et al.  Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance , 2008, BMC Medical Genomics.

[39]  W. Seeger,et al.  NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. , 2008, Antioxidants & redox signaling.

[40]  H. Beppu,et al.  Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension , 2008, Circulation.

[41]  M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[42]  M. Crabtree,et al.  Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. , 2008, American journal of physiology. Heart and circulatory physiology.

[43]  Crystal Kantores,et al.  Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[44]  Wolfgang M Kuebler,et al.  Intravital microscopy of the murine pulmonary microcirculation. , 2008, Journal of applied physiology.

[45]  J. Zweier,et al.  Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4 , 2007, Proceedings of the National Academy of Sciences.

[46]  W. Seeger,et al.  Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.

[47]  D. Curiel,et al.  Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[48]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[49]  J. Cogan,et al.  High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[50]  R. Brandes,et al.  Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia , 2006, British journal of pharmacology.

[51]  S. Black,et al.  Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[52]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[53]  R. Benza,et al.  Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[54]  D. Stewart,et al.  Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension , 2006, Circulation research.

[55]  M. Humbert,et al.  BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension , 2006, Human mutation.

[56]  T. Rabelink,et al.  Tetrahydrobiopterin, but Not l-Arginine, Decreases NO Synthase Uncoupling in Cells Expressing High Levels of Endothelial NO Synthase , 2006, Hypertension.

[57]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[58]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[59]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[60]  E. Jackson,et al.  Estradiol Metabolites Attenuate Monocrotaline-Induced Pulmonary Hypertension in Rats , 2005, Journal of cardiovascular pharmacology.

[61]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[62]  K. Rockett,et al.  Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension , 2005, Circulation.

[63]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[64]  M. Gladwin,et al.  Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator , 2004, Nature Medicine.

[65]  R. Tuder,et al.  Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle , 2004, Circulation research.

[66]  M. Humbert,et al.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.

[67]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[68]  P. V. van Heerden,et al.  The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS-a pilot human trial. , 2004, Journal of critical care.

[69]  N. Alp,et al.  Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[70]  James C Moon,et al.  Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. , 2004, American heart journal.

[71]  R. Trembath,et al.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.

[72]  M. Gladwin,et al.  Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation , 2003, Nature Medicine.

[73]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[74]  C. Frampton,et al.  B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.

[75]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[76]  U. Janssens,et al.  brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[77]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[78]  S. Archer,et al.  Diversity in Mitochondrial Function Explains Differences in Vascular Oxygen Sensing , 2002, Circulation research.

[79]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[80]  J. Joseph,et al.  The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. , 2002, The Biochemical journal.

[81]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[82]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[83]  S. Wedgwood,et al.  ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[84]  G. Castro [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[85]  S. Narumiya,et al.  Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. , 2001, American journal of respiratory and critical care medicine.

[86]  N. Voelkel,et al.  Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. , 2001, Journal of applied physiology.

[87]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[88]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[89]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[90]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[91]  P. Huang,et al.  The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.

[92]  J. Orens,et al.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.

[93]  M. Yacoub,et al.  High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension , 1998, The Journal of pathology.

[94]  J B Seward,et al.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[95]  W. Auger,et al.  Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.

[96]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[97]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[98]  S. Narumiya,et al.  cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. , 1994, The Journal of biological chemistry.

[99]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[100]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[101]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[102]  A. Malik,et al.  Pulmonary microvascular endothelial cells constitutively release xanthine oxidase. , 1992, Archives of biochemistry and biophysics.

[103]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[104]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[105]  H. Imura,et al.  Increased human brain natriuretic peptide in congestive heart failure. , 1990, The New England journal of medicine.

[106]  W. Smith,et al.  The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.

[107]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[108]  D. Buff Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[109]  B. Groves,et al.  PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY , 1987 .

[110]  W. Chung,et al.  A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[111]  M. Rubenfire,et al.  Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[112]  D. Bluemke,et al.  Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. , 2011, AJR. American journal of roentgenology.

[113]  R. Folz,et al.  Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.

[114]  P. Jones,et al.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.

[115]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.

[116]  M. Humbert,et al.  Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[117]  S. Archer,et al.  Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. , 1996, Cardiovascular research.

[118]  F. Haddad,et al.  Pulmonary Circulation | April-june 2012 | Vol 2 | No 2 Review Ar Ticle Diagnosis and Management of Pulmonary Hypertension Associated with Left Ventricular Diastolic Dysfunction , 2022 .